GlassScriptPhysician profile
Melissa L Leoni
NPI 1184675746
$5,834.94
in general payments reported to CMS, 2019-2025
24 companies · $961 in 2025
The $961 reported for 2025 was more than what 90% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $803 · 2020: $400 · 2021: $1,029 · 2022: $955 · 2023: $1,016 · 2024: $670 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,647.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,930.27 | 2019-2025 | Dailies Total1, Clareon, Simbrinza |
| Sun Pharmaceutical Industries INC. | $586.49 | 2021-2025 | Cequa |
| Bausch & Lomb Americas INC. | $554.35 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $385.09 | 2019-2021 | |
| Johnson & Johnson Vision Care, INC. | $379.82 | 2019-2025 | Acuvue |
| Abbvie INC. | $277.70 | 2022-2025 | |
| Eyevance Pharmaceuticals LLC | $217.74 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $200.86 | 2023-2025 | Soliris |
| Novartis Pharmaceuticals Corporation | $163.38 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $146.74 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $139.24 | 2022-2024 | Tyrvaya |
| Lkc Technologies, INC. | $131.69 | 2023-2024 | |
| Horizon Therapeutics Plc | $124.40 | 2022 | |
| Optos, INC. | $121.68 | 2019-2020 | |
| Lombart Brothers, INC. | $119.21 | 2025 | Opd-III |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $89.60 | 2024 | Syfovre |
| Allergan, INC. | $87.65 | 2019-2021 | |
| Shire North American Group INC | $49.63 | 2019 | |
| Dompe US, INC. | $32.63 | 2021-2025 | Oxervate |
| Harrow Eye, LLC | $21.85 | 2024 | Vevye |
| Biotissue Holdings INC. | $21.51 | 2025 | |
| Aerie Pharmaceuticals, INC. | $20.90 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $16.98 | 2019 | |
| Thea Pharma INC. | $15.53 | 2025 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Leoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.